MCID: VRL003
MIFTS: 47

Variola Major

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Variola Major

MalaCards integrated aliases for Variola Major:

Name: Variola Major 12 15 73
Smallpox 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050508
ICD9CM 35 050.0
SNOMED-CT 68 47452006

Summaries for Variola Major

Disease Ontology : 12 A smallpox that results in severe infection, located in skin, has material basis in Variola virus. The infection results in_formation_of lesions.

MalaCards based summary : Variola Major, also known as smallpox, is related to smallpox and variola minor, and has symptoms including fever, pruritus and exanthema. An important gene associated with Variola Major is TLR3 (Toll Like Receptor 3), and among its related pathways/superpathways are Akt Signaling and IL-2 Pathway. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and t cells, and related phenotypes are neoplasm and respiratory system

Wikipedia : 76 Smallpox was an infectious disease caused by one of two virus variants, variola major and variola minor.... more...

Related Diseases for Variola Major

Diseases related to Variola Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 smallpox 32.5 IFNG IL2
2 variola minor 11.5
3 vaccinia 10.1
4 campylobacteriosis 10.1 IFNG TLR4
5 hepatitis e 10.1 IFNG TLR3
6 myositis fibrosa 10.1 IFNG TLR4
7 allergic conjunctivitis 10.1 IFNG TLR3
8 hyper ige syndrome 10.1 IFNG TLR4
9 invasive aspergillosis 10.1 IFNG TLR4
10 aspergillosis 10.1 IFNG TLR4
11 q fever 10.1 IFNG TLR4
12 dengue hemorrhagic fever 10.1 IFNG TLR3
13 echinococcosis 10.1 IFNG TLR4
14 melioidosis 10.1 IFNG TLR4
15 orofacial granulomatosis 10.1 CCL3 IFNG
16 typhoid fever 10.1 IFNG TLR4
17 boutonneuse fever 10.1 IL2 TLR4
18 salmonellosis 10.1 IFNG TLR4
19 cutaneous leishmaniasis 10.0 IFNG TLR4
20 fixed drug eruption 10.0 IFNG IL2
21 berylliosis 10.0 IFNG IL2
22 atopic keratoconjunctivitis 10.0 IFNG IL2
23 keratoconjunctivitis 10.0 IFNG IL2
24 conjunctivitis 10.0 IFNG IL2
25 lymphadenitis 10.0 IFNG TLR4
26 clonorchiasis 10.0 IFNG IL2
27 crohn's colitis 10.0 IFNG IL2
28 chronic active epstein-barr virus infection 10.0 IFNG IL2
29 intermediate uveitis 10.0 IFNG IL2
30 posterior uveitis 10.0 IFNG IL2
31 chlamydia 10.0 IFNG TLR4
32 erythema multiforme 10.0 IFNG IL2
33 coccidiosis 10.0 IFNG IL2
34 hematopoietic stem cell transplantation 10.0 IFNG IL2
35 vernal conjunctivitis 10.0 IFNG IL2
36 stevens-johnson syndrome/toxic epidermal necrolysis 10.0 IFNG IL2
37 autoimmune disease of endocrine system 10.0 IFNG IL2
38 hypersensitivity reaction type iv disease 10.0 IFNG IL2
39 toxoplasmosis 10.0 IFNG TLR4
40 acute graft versus host disease 10.0 IFNG IL2
41 lepromatous leprosy 10.0 IFNG IL2
42 autoimmune uveitis 10.0 IFNG IL2
43 testicular disease 10.0 IFNG IL2
44 pleurisy 10.0 IFNG IL2
45 herpes zoster 10.0 IFNG IL2
46 tropical spastic paraparesis 10.0 IFNG IL2
47 tonsillitis 10.0 IFNG IL2
48 mumps 10.0 IFNG IL2
49 parasitic protozoa infectious disease 10.0 IFNG IL2
50 leprosy 3 10.0 IFNG IL2

Graphical network of the top 20 diseases related to Variola Major:



Diseases related to Variola Major

Symptoms & Phenotypes for Variola Major

UMLS symptoms related to Variola Major:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Variola Major:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.26 IFNG IL2 TLR3 TLR4
2 respiratory system MP:0005388 8.92 IFNG IL2 TLR3 TLR4

Drugs & Therapeutics for Variola Major

Drugs for Variola Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 1
4 gamma-Globulins Phase 4,Phase 2,Phase 1
5 Antibodies Phase 4,Phase 2,Phase 1
6 Immunoglobulins Phase 4,Phase 2,Phase 1
7 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 1
8 Iron-Dextran Complex Phase 3
9
Phenol Approved, Experimental Phase 2 108-95-2 996
10
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
11 tannic acid Approved Phase 1, Phase 2
12
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
13 Pharmaceutical Solutions Phase 1
14 Natriuretic Agents Phase 1
15 diuretics Phase 1
16 interferons Phase 1
17 Krestin Phase 1
18 Protective Agents Phase 1
19 Antibiotics, Antitubercular Phase 1
20 Radiation-Protective Agents Phase 1
21 Antiviral Agents Phase 1
22 Anti-Bacterial Agents Phase 1
23 Adjuvants, Immunologic Phase 1
24 Anti-Infective Agents Phase 1
25 Interferon Inducers Phase 1
26 Keyhole-limpet hemocyanin Phase 1
27 Liver Extracts Phase 1
28 Cathartics Phase 1
29 Carboxymethylcellulose Sodium Phase 1
30 Poly ICLC Phase 1
31 Laxatives Phase 1
32 Poly I-C Phase 1
33 Gastrointestinal Agents Phase 1
34 Interferon-gamma

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV) Completed NCT01158157 Phase 4
2 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
3 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
4 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
5 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
6 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
7 Safety and Efficacy of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
8 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat Completed NCT02474589 Phase 3 tecovirimat
9 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
10 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
11 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Not yet recruiting NCT03699124 Phase 3
12 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
13 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
14 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
15 Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults Completed NCT00053482 Phase 2
16 Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
17 Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Completed NCT00258947 Phase 2
18 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
19 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
20 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
21 A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
22 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
23 Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. Completed NCT00189956 Phase 2
24 Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® Completed NCT01827371 Phase 2
25 A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects Completed NCT00316524 Phase 2
26 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
27 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
28 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2
29 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
30 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
31 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients Completed NCT00316589 Phase 2
32 A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis Completed NCT00316602 Phase 2
33 Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients Completed NCT00189904 Phase 1, Phase 2
34 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
35 Dryvax Dilution-Prev Vacc Adults Completed NCT00032708 Phase 2
36 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
37 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
38 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
39 A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites Completed NCT00890760 Phase 1, Phase 2
40 PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
41 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
42 EMaBS TB Vaccine Study Not yet recruiting NCT03681860 Phase 1, Phase 2
43 Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Terminated NCT00053508 Phase 2
44 Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults Completed NCT00079820 Phase 1
45 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® Completed NCT00042094 Phase 1
46 Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects Completed NCT00189969 Phase 1
47 Human Immune Responses Smallpox Completed NCT00068198 Phase 1
48 Safety and Immunogenicity of CJ-50300 Completed NCT00336635 Phase 1
49 Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects Completed NCT00565929 Phase 1 Placebo
50 A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers Completed NCT00002261 Phase 1

Search NIH Clinical Center for Variola Major

Genetic Tests for Variola Major

Anatomical Context for Variola Major

The Foundational Model of Anatomy Ontology organs/tissues related to Variola Major:

19
Skin

MalaCards organs/tissues related to Variola Major:

41
Skin, T Cells, Bone, Tonsil, Testes, B Cells, Heart

Publications for Variola Major

Articles related to Variola Major:

(show top 50) (show all 413)
# Title Authors Year
1
Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. ( 30453097 )
2019
2
A Case Series of Smallpox Vaccination-Associated Myopericarditis: Effects on Safety and Readiness of the Active Duty Soldier. ( 29947793 )
2018
3
Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccine. ( 30048524 )
2018
4
An antiviral for smallpox. ( 30082865 )
2018
5
Smallpox Autoinoculation Via Tattoo in a Soldier. ( 30085282 )
2018
6
Bayesian Phylogeography and Pathogenic Characterization of Smallpox Based on HA, ATI, and CrmB Genes. ( 30099520 )
2018
7
The spectre of smallpox lingers. ( 30104592 )
2018
8
First Smallpox Drug Approved. ( 30140861 )
2018
9
Smallpox antiviral ends decades-long search. ( 30188546 )
2018
10
Drug Approved to Treat Smallpox After a Bioterrorist Attack. ( 30358593 )
2018
11
Long-term effects of smallpox vaccination on expression of the HIV-1 co-receptor CCR5 in women. ( 30440008 )
2018
12
Oral Tecovirimat for the Treatment of Smallpox. ( 30462945 )
2018
13
Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox - Part II. ( 30488769 )
2018
14
The last case of smallpox. ( 30507458 )
2018
15
Variola minor in coalfield areas of England and Wales, 1921-34: Geographical determinants of a national smallpox epidemic that spread out of effective control. ( 28351006 )
2017
16
The Threat of Synthetic Smallpox: European Perspectives. ( 29178813 )
2017
17
Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. ( 27357167 )
2016
18
An interaction quantitative trait loci tool implicates epistatic functional variants in an apoptosis pathway in smallpox vaccine eQTL data. ( 27052692 )
2016
19
The prevention and eradication of smallpox: a commentary on Sloane (1755) 'An account of inoculation'. ( 25750241 )
2015
20
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky. ( 25921466 )
2015
21
Reply to "Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky". ( 25921467 )
2015
22
Game theory of pre-emptive vaccination before bioterrorism or accidental release of smallpox. ( 25926701 )
2015
23
Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response. ( 25930115 )
2015
24
Smallpox: 12,000 years from plagues to eradication: a dermatologic ailment shaping the face of society. ( 25970158 )
2015
25
Risks Associated With Smallpox Vaccination in Pregnancy: A Systematic Review and Meta-analysis. ( 26000516 )
2015
26
The rediscovery of smallpox. ( 24438205 )
2014
27
Smallpox vaccination, colonial Sydney and serendipity. ( 24641158 )
2014
28
Smallpox and globalization or the first achieved plannetary goal. ( 24697019 )
2014
29
The smallpox threat: a time to reconsider global policy. ( 24712454 )
2014
30
Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000. ( 24759651 )
2014
31
Infectious diseases: Smallpox watch. ( 24784198 )
2014
32
Are we there yet? The smallpox research agenda using variola virus. ( 24789223 )
2014
33
John Haygarth's 18th-century 'rules of prevention' for eradicating smallpox. ( 25504607 )
2014
34
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. ( 23254433 )
2013
35
Contact transmission of vaccinia virus from smallpox vaccinees in the United States, 2003-2011. ( 22192851 )
2012
36
Genome-wide association study of antibody response to smallpox vaccine. ( 22542470 )
2012
37
Mousepox, a small animal model of smallpox. ( 22688768 )
2012
38
Remaining questions about clinical variola major. ( 21470458 )
2011
39
The discontinuation of routine smallpox vaccination in the United States, 1960-1976: an unlikely affirmation of biomedical hegemony. ( 21340322 )
2011
40
Smallpox vaccine safety is dependent on T cells and not B cells. ( 21450994 )
2011
41
Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine. ( 21592983 )
2011
42
From smallpox eradication to contemporary global health initiatives: enhancing human capacity towards a global public health goal. ( 22185838 )
2011
43
A brief history of smallpox eradication in Iran. ( 20039774 )
2010
44
Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine. ( 20214479 )
2010
45
An active participant in the eradication program of smallpox. ( 20586232 )
2010
46
Studies of the suitability of fowlpox as a decontamination and thermal stability simulant for variola major. ( 20148078 )
2009
47
Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis. ( 19345728 )
2009
48
Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. ( 19004937 )
2009
49
In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC. ( 18804965 )
2009
50
Gender effects on humoral immune responses to smallpox vaccine. ( 19200827 )
2009

Variations for Variola Major

Expression for Variola Major

Search GEO for disease gene expression data for Variola Major.

Pathways for Variola Major

Pathways related to Variola Major according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 CCL3 IL2 TLR3 TLR4
2
Show member pathways
12.88 IFNG IL2 TLR3 TLR4
3
Show member pathways
12.5 IFNG TLR3 TLR4
4
Show member pathways
12.43 IL2 TLR3 TLR4
5
Show member pathways
12.42 IFNG IL2 TLR3 TLR4
6
Show member pathways
12.31 IFNG IL2 TLR4
7 12.27 IFNG IL2 TLR3
8
Show member pathways
12.21 CCL3 IFNG IL2 TLR3 TLR4
9
Show member pathways
12.03 IFNG TLR3 TLR4
10
Show member pathways
11.92 IFNG TLR3 TLR4
11 11.89 IFNG TLR3 TLR4
12
Show member pathways
11.82 CCL3 IFNG IL2
13
Show member pathways
11.75 IL2 TLR3 TLR4
14 11.71 IFNG IL2 TLR4
15
Show member pathways
11.63 CCL3 IFNG IL2
16 11.6 TLR3 TLR4
17 11.58 IFNG IL2
18
Show member pathways
11.55 IFNG IL2
19 11.53 IFNG IL2
20 11.5 CCL3 IFNG TLR4
21 11.47 IFNG IL2
22
Show member pathways
11.45 IFNG IL2
23
Show member pathways
11.43 IFNG IL2
24 11.43 CCL3 IFNG TLR4
25 11.34 IFNG IL2
26 11.34 CCL3 IFNG IL2
27 11.31 IFNG TLR4
28 11.3 IFNG IL2
29 11.29 IFNG TLR4
30 11.27 IFNG IL2
31 11.18 CCL3 IFNG IL2
32 11.09 IFNG IL2
33
Show member pathways
11.04 IFNG IL2 TLR3 TLR4
34 11.03 IFNG IL2
35 10.99 IFNG IL2
36 10.95 IFNG IL2
37 10.9 TLR3 TLR4

GO Terms for Variola Major

Cellular components related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.02 CCL3 IFNG IL2 TLR3 TLR4

Biological processes related to Variola Major according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.83 CCL3 IFNG IL2
2 inflammatory response GO:0006954 9.81 CCL3 TLR3 TLR4
3 immune response GO:0006955 9.78 CCL3 IFNG IL2 TLR4
4 positive regulation of gene expression GO:0010628 9.71 CCL3 IFNG TLR3 TLR4
5 positive regulation of JNK cascade GO:0046330 9.67 TLR3 TLR4
6 cellular response to mechanical stimulus GO:0071260 9.66 TLR3 TLR4
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.66 IFNG IL2
8 apoptotic signaling pathway GO:0097190 9.65 TLR3 TLR4
9 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 TLR3 TLR4
10 positive regulation of interleukin-6 production GO:0032755 9.64 TLR3 TLR4
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.64 TLR3 TLR4
12 extrinsic apoptotic signaling pathway GO:0097191 9.63 IFNG TLR3
13 positive regulation of interferon-gamma production GO:0032729 9.62 IL2 TLR4
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 IFNG TLR4
15 positive regulation of B cell proliferation GO:0030890 9.61 IL2 TLR4
16 toll-like receptor signaling pathway GO:0002224 9.61 TLR3 TLR4
17 cellular response to interferon-gamma GO:0071346 9.61 CCL3 TLR3 TLR4
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.6 CCL3 TLR4
19 positive regulation of interleukin-1 beta secretion GO:0050718 9.59 CCL3 TLR4
20 positive regulation of interleukin-8 production GO:0032757 9.58 TLR3 TLR4
21 positive regulation of interferon-beta production GO:0032728 9.58 TLR3 TLR4
22 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.57 TLR3 TLR4
23 positive regulation of chemokine production GO:0032722 9.56 TLR3 TLR4
24 necroptotic process GO:0070266 9.55 TLR3 TLR4
25 regulation of regulatory T cell differentiation GO:0045589 9.54 IFNG IL2
26 I-kappaB phosphorylation GO:0007252 9.52 TLR3 TLR4
27 negative regulation of interleukin-17 production GO:0032700 9.51 IFNG TLR4
28 positive regulation of tumor necrosis factor production GO:0032760 9.5 CCL3 TLR3 TLR4
29 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.49 TLR3 TLR4
30 positive regulation of interferon-beta biosynthetic process GO:0045359 9.46 TLR3 TLR4
31 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.37 TLR3 TLR4
32 positive regulation of interleukin-12 production GO:0032735 9.33 IFNG TLR3 TLR4
33 regulation of dendritic cell cytokine production GO:0002730 9.26 TLR3 TLR4
34 negative regulation of osteoclast differentiation GO:0045671 9.13 CCL3 TLR3 TLR4
35 positive regulation of inflammatory response GO:0050729 8.92 CCL3 IL2 TLR3 TLR4

Molecular functions related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL3 IFNG IL2

Sources for Variola Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....